- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Spotlight Stock Market: Market Notice 237/24 - Xoma AB will be listed on Spotlight Stock Market on November 22, 2024 | 3 | Cision News | ||
| 07.11. | XOMA Corporation: XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities | 78 | GlobeNewswire (Europe) | Zevra's MIPLYFFA (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience's portfolio... ► Artikel lesen | |
| 07.11. | XOMA Royalty Corp - 8-K, Current Report | - | SEC Filings | ||
| 07.11. | XOMA Royalty Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 29.10. | XOMA stock soars to 52-week high, reaching $30.7 | 1 | Investing.com | ||
| XOMA CORPORATION PREF Aktie jetzt für 0€ handeln | |||||
| 29.10. | XOMA-Aktie erreicht 52-Wochen-Hoch bei 30,7 US-Dollar | 3 | Investing.com Deutsch | ||
| 22.10. | Twist Bioscience enters into purchase agreement with XOMA Royalty | 10 | Seeking Alpha | ||
| 22.10. | XOMA Royalty Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 22.10. | XOMA Corporation: XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience | 3 | GlobeNewswire (USA) | ||
| 21.10. | XOMA stock hits 52-week high at $26.48 amid market optimism | 4 | Investing.com | ||
| 03.10. | Dividendenbekanntmachungen (03.10.2024) | 4.201 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABM INDUSTRIES INC US0009571003 0,225 USD 0,2036 EUR AG BARR PLC GB00B6XZKY75 0,031 GBP 0,0372 EUR ALLIANCEBERNSTEIN GLOBAL HIGH... ► Artikel lesen | |
| 23.09. | XOMA shares hold as analyst reiterates Buy rating post-FDA nod | 6 | Investing.com | ||
| 23.09. | XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend | 3 | Seeking Alpha | ||
| 23.09. | XOMA Preferred Shares Series A declares $0.5391 dividend | 7 | Seeking Alpha | ||
| 23.09. | XOMA Royalty gewinnt FDA-zugelassenes Produkt für NPC | 4 | Investing.com Deutsch | ||
| 23.09. | XOMA Corporation: Zevra's MIPLYFFA (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) | 101 | GlobeNewswire (Europe) | MIPLYFFA is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA sales and up to $52.6 million... ► Artikel lesen | |
| 23.09. | XOMA Royalty gains FDA-approved asset for NPC | 1 | Investing.com | ||
| 23.09. | XOMA Royalty Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 23.09. | XOMA Corporation: XOMA Royalty Declares Quarterly Preferred Stock Dividends | 4 | GlobeNewswire (USA) | ||
| 04.09. | XOMA Corporation: XOMA Royalty to Present at Upcoming Investor Conferences in September | 2 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,500 | -15,59 % | Evotec Aktie: Wie die Markttrends beeinflussen | ||
| QIAGEN | 41,045 | +2,05 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
| ARCELLX | 90,44 | +3,69 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| BIONTECH | 108,90 | +0,28 % | GOLDMAN SACHS stuft Biontech auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Biontech mit einem Kursziel von 137 US-Dollar auf "Buy" belassen. Der Forschungs- und Entwicklungstag habe insgesamt... ► Artikel lesen | |
| DYNE THERAPEUTICS | 29,690 | -0,27 % | Dyne Therapeutics: Leitender Vizepräsident veräußert Aktien im Wert von 77.127 US-Dollar | ||
| KYMERA THERAPEUTICS | 44,980 | +3,38 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update | KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| KEROS THERAPEUTICS | 55,92 | +3,86 % | Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | ||
| MODERNA | 39,575 | +0,18 % | Starke Nachfrage treibt Kurs der Aktie von Moderna (36,0218 €) | Im US-amerikanischen Wertpapierhandel brilliert aktuell die Moderna-Aktie . Der Titel steigt deutlich. Grund zur Freude haben Aktionäre von Moderna: Die Aktie weist zur Stunde eine Verteuerung von 3... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,79 | +0,01 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,290 | +2,68 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 39,030 | +7,52 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 7,790 | -2,50 % | 4D Molecular initiated by Morgan Stanley at underweight | ||
| RELAY THERAPEUTICS | 4,750 | +2,37 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights | Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of... ► Artikel lesen |
Das Unternehmen XOMA CORPORATION PREF kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,400 (+1,67 %) liegt der Kurs bei 24,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XOMA CORPORATION PREF finden Sie auf Wallstreet Online.
